Literature DB >> 15072453

Remission of a chiasmatic glioma in a non-NF1 patient after brief chemotherapy with vincristine and carboplatin: case report and literature review.

Elpis Mantadakis1, Maria Raissaki, Vassiliki Danilatou, Alexander Kambourakis, Eftichia Stiakaki, Maria Kalmanti.   

Abstract

We describe the case of an 8-year-old girl without neurofibromatosis, who presented with total loss of vision on the left eye, due to a chiasmatic mass with imaging characteristics of glioma, accompanied by a second asymptomatic mass in the middle cranial fossa, along the intracranial route of the right trigeminal nerve. The patient received a total of 10 weekly injections of vincristine and four injections of carboplatin every 3 weeks and achieved a very good partial response (97% volume reduction) after the nineth week of therapy with acceptable toxicity. Given the natural history of opticochiasmatic gliomas, we cannot rule out the possibility of a spontaneous regression. However, we believe the quick response accompanied by visual improvement was most likely due to chemotherapy. A trial of vincristine and carboplatin may be worthwhile in children with symptomatic chiasmatic gliomas, irrespective of their age.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15072453     DOI: 10.1023/b:neon.0000021740.50003.27

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  30 in total

1.  Spontaneous visual improvement in chiasmal gliomas.

Authors:  G T Liu; S Lessell
Journal:  Am J Ophthalmol       Date:  1992-08-15       Impact factor: 5.258

2.  Regression after biopsy of a pilocytic opticochiasmatic astrocytoma in a young adult without neurofibromatosis.

Authors:  C Colosimo; A Cerase; G Maira
Journal:  Neuroradiology       Date:  2000-05       Impact factor: 2.804

3.  Spontaneous remission of chiasmatic/hypothalamic masses in neurofibromatosis type 1: report of two cases.

Authors:  S Gottschalk; R Tavakolian; A Buske; S Tinschert; R Lehmann
Journal:  Neuroradiology       Date:  1999-03       Impact factor: 2.804

4.  Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study.

Authors:  D H Mahoney; M E Cohen; H S Friedman; J L Kepner; L Gemer; J W Langston; H E James; P K Duffner; L E Kun
Journal:  Neuro Oncol       Date:  2000-10       Impact factor: 12.300

5.  Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas.

Authors:  R J Packer; J Ater; J Allen; P Phillips; R Geyer; H S Nicholson; R Jakacki; E Kurczynski; M Needle; J Finlay; G Reaman; J M Boyett
Journal:  J Neurosurg       Date:  1997-05       Impact factor: 5.115

Review 6.  Spontaneous regression of low-grade astrocytomas in childhood.

Authors:  S M Schmandt; R J Packer; L G Vezina; J Jane
Journal:  Pediatr Neurosurg       Date:  2000-03       Impact factor: 1.162

Review 7.  An integrated approach to the treatment of chiasmatic-hypothalamic gliomas.

Authors:  M Garvey; R J Packer
Journal:  J Neurooncol       Date:  1996 May-Jun       Impact factor: 4.130

8.  Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas.

Authors:  Dennis J Kuo; Howard L Weiner; Jeffrey Wisoff; Douglas C Miller; Edmond A Knopp; Jonathan L Finlay
Journal:  J Pediatr Hematol Oncol       Date:  2003-05       Impact factor: 1.289

9.  Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study.

Authors:  R Listernick; J Charrow; M Greenwald; M Mets
Journal:  J Pediatr       Date:  1994-07       Impact factor: 4.406

10.  Recurrent chiasmatic-hypothalamic glioma treated with oral etoposide.

Authors:  M C Chamberlain; M R Grafe
Journal:  J Clin Oncol       Date:  1995-08       Impact factor: 44.544

View more
  1 in total

Review 1.  Visual prognosis of optic glioma.

Authors:  Jeong-Min Hwang; Jung-Eun Cheon; Kyu-Chang Wang
Journal:  Childs Nerv Syst       Date:  2008-01-04       Impact factor: 1.475

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.